Laura Howes
Journo for @cenmag with a taste for biomolecules; All opinions are mine, all mine. She/her. DMs open. I say my name like this: https://t.co/a8q204f3Xh
Articles
-
2 weeks ago |
cen.acs.org | Laura Howes
The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values CureVac at around $1.25 billion. Once complete, CureVac will be wholly absorbed into BioNTech. CureVac wasn't forced into this deal by a lack of cash, however. The company has approximately €438.3 million ($507.9 million) cash on its balance sheet, enough to tide it over until 2028, according to its first-quarter financial results published on May 20.
-
2 weeks ago |
cen.acs.org | Laura Howes
Radiopharmaceutical company RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb, will license a therapeutic and diagnostic asset for prostate cancer from Philochem. The deal is worth $350 million up front, with another $1 billion in development, regulatory, and commercial milestones. For that sum, RayzeBio will get global rights to OncoACP3, a small-molecule ligand that targets acid phosphatase 3 (ACP3).
-
3 weeks ago |
cen.acs.org | Laura Howes
The amino acid taurine is one of the building blocks of the proteins in our bodies and plays multiple other roles in biology. And while previous research has suggested that low levels of taurine may signal-or even drive-aging, a new longitudinal study by Rafael de Cabo and his team at the US National Institute on Aging (NIA) says the answer is more complicated ( Science 2025, DOI: 10.1126/science.adl2116). In 2023 a team led by Vijay K.
-
2 months ago |
cen.acs.org | Laura Howes
Seeking to enhance its presence in cancer drugs and the US, the German drug company Merck KGaA is buying the oncology biotech SpringWorks Therapeutics for $3.9 billion. The deal is expected to close in the second half of the year.
-
Mar 26, 2025 |
cen.acs.org | Laura Howes
At the American Chemical Society Spring 2025 meeting on Tuesday, Ed Griffen of MedChemica disclosed the structure of a pancoronavirus antiviral that targets the main protease (M pro ) of the two different coronaviruses that cause Middle East respiratory syndrome (MERS) and COVID-19. The antiviral, ASAP-0017445, was presented as part of a digital session titled "Developing Countermeasures for Viruses of Pandemic Potential" organized by the Division of Medicinal Chemistry of the ACS.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 20K
- DMs Open
- Yes
RT @rowanwalrath: I am so honored that a feature I published in @cenmag in September, "R&D for long COVID is collapsing," was selected as…
🍿
Big Pharma has no problem committing billions to moving part of its manufacturing to the US to appease Trump, but they'll fight MFN pricing tooth and nail. I don't see Trump making it stick. But the new bomb throwing destabilizes the industry even more. Heckuva sorry excuse for
RT @derJamesJackson: The CDU-SPD government are choosing gas over nuclear. The Greens have a lot to answer for
